What If Blood Types Were Never Discovered?

Blood transfusion had been attempted, with wildly inconsistent results, since at least the seventeenth century, when early experiments (including, notoriously, transfusing animal blood into human patients) produced a mixture of apparent successes and deaths that nobody at the time could adequately explain. By the nineteenth century, human-to-human blood transfusion was being attempted more seriously, particularly for severe blood loss during childbirth, but remained a genuine gamble — some patients recovered dramatically, others died within minutes of the procedure beginning, seemingly at random, with no reliable way to predict which outcome a given transfusion would produce.

Karl Landsteiner, an Austrian physician and biologist working in Vienna, investigated this mystery systematically starting around 1900, collecting blood samples from himself and his laboratory colleagues and testing every possible combination by mixing them on glass slides, observing whether the red blood cells remained evenly distributed or clumped together (agglutinated) — a reaction that, he correctly deduced, was the mechanism causing fatal transfusion reactions. Through this systematic testing, Landsteiner identified three distinct blood types in 1901 (a fourth, AB, was identified shortly after by colleagues building on his work), establishing what became known as the ABO blood group system and explaining, for the first time, why transfusions between compatible blood types succeeded while incompatible combinations could prove fatal. Landsteiner received the Nobel Prize in Physiology or Medicine in 1930 for this discovery, and later, in 1940, also contributed to identifying the Rh blood factor, another critical compatibility system, particularly significant for pregnancy complications.

Landsteiner's discovery depended on a specific, systematic research approach — methodically testing blood combinations rather than continuing to treat transfusion reactions as an unpredictable, poorly understood risk — that wasn't guaranteed to occur when or how it did. Imagine Landsteiner pursuing a different research focus during this period, or his systematic blood-mixing investigation simply not occurring to him or any other contemporary researcher as a promising approach to the long-standing transfusion mystery.

Given how significant and puzzling the transfusion problem had been for centuries, with many physicians and researchers aware something explained the pattern of success and failure without knowing what, a complete permanent failure to ever identify blood type incompatibility seems relatively unlikely — but a meaningfully delayed discovery, pushed back by one or several decades to whichever other researcher eventually pursues a comparably systematic investigation, represents a genuinely plausible divergence from the actual 1901 timeline.

In the years immediately following a delayed blood type discovery, blood transfusion continues as the same unpredictable, high-risk procedure it had been for centuries — physicians attempting transfusions for severe blood loss, particularly during childbirth or major trauma, would have no reliable way to predict whether a given transfusion would save the patient or trigger a fatal reaction, meaning the procedure would likely remain a last-resort intervention attempted only when the alternative (continued blood loss) was considered even more certainly fatal.

The First World War, which began just over a decade after Landsteiner's actual discovery and saw blood transfusion become an increasingly important tool for treating severely wounded soldiers as understanding of blood type compatibility spread through military medical practice during the war itself, would instead see this same scale of battlefield casualties treated without any reliable transfusion capability, meaning soldiers who might otherwise have survived severe blood loss with a compatible transfusion would instead face significantly higher mortality from wounds that, with the actual timeline's blood type knowledge, became increasingly treatable as the war progressed.

For individual patients and families facing severe blood loss, particularly the significant historical risk of maternal death from postpartum hemorrhage during childbirth, a world without reliable blood type knowledge means transfusion remains a genuine gamble rather than a dependable medical intervention, meaning the specific safety net blood transfusion eventually provided for exactly this kind of medical emergency simply isn't available in anything like its actual reliable form, and physicians facing a hemorrhaging patient would need to weigh the same fundamental uncertainty about whether attempting a transfusion would help or actively worsen the outcome.

Surgery more broadly, particularly major operations carrying significant blood loss risk, would also remain considerably more dangerous and limited in scope without reliable transfusion capability as a backup for cases where bleeding exceeded what a patient's own body could safely tolerate — surgeons would need to remain correspondingly more conservative about which procedures were worth attempting given this persistent, unmitigated risk, likely constraining the scope and ambition of major surgery in ways comparable to how anesthesia's absence (covered in a separate scenario on this site) constrained earlier surgical practice for different reasons.

At the broadest scale, reliable blood transfusion, built directly on blood type compatibility knowledge, became an essential component of nearly every area of modern medicine: emergency trauma care, major surgery, cancer treatment (chemotherapy often severely depletes blood cell counts, requiring transfusion support), obstetric care, and the entire modern blood banking and donation system that developed over the following decades to make compatible blood readily available when needed. A world where blood type compatibility remains unknown or poorly understood for decades longer plausibly means this entire subsequent medical infrastructure and set of treatment capabilities develops considerably later and more slowly, with a correspondingly higher cumulative toll from otherwise treatable blood loss across every one of these medical contexts.

The Rh blood factor, which Landsteiner also helped identify in 1940 and which proved particularly significant for a specific and serious pregnancy complication (Rh incompatibility between mother and fetus, which can cause severe complications in certain circumstances), represents a related but somewhat separate discovery that plausibly follows a comparably delayed timeline in this counterfactual, given how directly the later Rh discovery built on the same research tradition and institutional momentum Landsteiner's original ABO discovery had established. A world with both discoveries delayed means specific, serious pregnancy complications related to blood type incompatibility between mother and child remain poorly understood and effectively untreatable for a considerably longer period.